Mena FN

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA'

SYDNEY, April 21, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in ...
FOX40 News

First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

SYDNEY, Dec. 22, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
Pharmabiz

Clarity Pharma begin patient dosing in phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company, announce that the first patient has been dosed in its pivotal phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, ...
BioWorld

Radiopharma Clarity touts advantages of its targeted copper theranostics

Clarity Pharmaceuticals Ltd. is progressing three of its targeted copper theranostics through the clinic that are based on its sarcophagine technology that securely holds copper isotopes inside a cage ...
Taiwan News

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
manilatimes

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
WRIC

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

SYDNEY, Oct. 14, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products ...
Yahoo Finance

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64 Cu-SAR-bisPSMA. SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both ...
Yahoo Finance

First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

First patient safely dosed in the pivotal Phase III 64 Cu-SAR-bisPSMA diagnostic trial, CLARIFY. The aim of the CLARIFY trial is to detect regional nodal metastases in participants with prostate ...
Pharmabiz

US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, announced ...
Finanznachrichten

Clarity Pharmaceuticals: Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...